Literature DB >> 8690450

Pulmonary immune memory: localized production of antibody in the lung after antigen challenge.

D E Bice1, B A Muggenburg.   

Abstract

In comparison to primary immune responses after lung immunization, the level of antigen-specific antibody and the number of cells producing specific antibody are significantly increased after challenging the lungs with antigen. The response of immune memory cells in the lung to an antigen challenge could be responsible for this elevated immune response. However, increased numbers of antibody-producing cells, possibly produced in the lung-associated lymph nodes, are also found in the blood after an antigen challenge. Therefore, it is possible that both the response of immune memory cells in the lung, and the recruitment of antibody-producing cells from the blood, contribute to the elevated levels of antibody in the lung after an antigen challenge. This study compared the level of antibody produced in the lung by the response of pulmonary immune memory cells with the level of antibody produced by antibody-forming cells that enter the lung from blood after an antigen challenge. This comparison was made possible by immunizing and challenging two lung lobes of dogs with two antigens. The immune responses to both antigens were then evaluated in both lung lobes after primary immunization and challenge. Data from these evaluations showed that most antibody in the lung after an antigen challenge is produced by a localized anamnestic response of pulmonary immune memory cells. A significantly lower level of antibody entered the lung from the vasculature and/or was produced by antibody-forming cells that entered the lung from blood after an antigen challenge.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690450      PMCID: PMC1456424          DOI: 10.1111/j.1365-2567.1996.tb00004.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes.

Authors:  J T DODGE; C MITCHELL; D J HANAHAN
Journal:  Arch Biochem Biophys       Date:  1963-01       Impact factor: 4.013

2.  Characterization of a circulating subpopulation of spontaneous antitetanus toxoid antibody producing B cells following in vivo booster immunization.

Authors:  R H Stevens; E Macy; C Morrow; A Saxon
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

3.  Kinetics of extravasation and redistribution of IgA-specific antibody-containing cells in the intestine.

Authors:  A J Husband
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

4.  The effect of splenectomy on the appearance of specific antibody-forming cells in lungs of dogs after intravenous immunization with sheep erythrocytes.

Authors:  H B Kaltreider; E Barth; C Pellegrini
Journal:  Exp Lung Res       Date:  1981-08       Impact factor: 2.459

5.  All KLH preparations are not created equal.

Authors:  A A Vandenbark; P Yoshihara; L Carveth; D R Burger
Journal:  Cell Immunol       Date:  1981-05-01       Impact factor: 4.868

6.  Detection of plaque-forming cells in the peripheral blood of actively immunized humans.

Authors:  P D Thomson; N S Harris
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

7.  Immune responses after localized lung immunization in the dog.

Authors:  D E Bice; D L Harris; J O Hill; B A Muggenburg; R K Wolff
Journal:  Am Rev Respir Dis       Date:  1980-11

8.  Transfer of memory cells into antigen-pretreated hosts. II. Influence of localized antigen on the migration of specific memory B cells.

Authors:  Y Baine; N M Ponzio; G J Thorbecke
Journal:  Eur J Immunol       Date:  1981-12       Impact factor: 5.532

9.  In vitro production of anti-influenza virus antibody after intranasal inoculation with cold-adapted influenza virus.

Authors:  R Yarchoan; B R Murphy; W Strober; M L Clements; D L Nelson
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

10.  Regional immunologic responses following localized deposition of antigen in the lung.

Authors:  D E Bice; D L Harris; B A Muggenburg
Journal:  Exp Lung Res       Date:  1980-03       Impact factor: 2.459

View more
  7 in total

Review 1.  Hidden risks for pneumonia in Malawi.

Authors:  D G Fullerton; S B Gordon
Journal:  Malawi Med J       Date:  2003-06       Impact factor: 0.875

2.  Local T-cell activation after segmental allergen challenge in the lungs of allergic dogs.

Authors:  Theo A Out; Shan-Ze Wang; Karin Rudolph; David E Bice
Journal:  Immunology       Date:  2002-04       Impact factor: 7.397

3.  Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease.

Authors:  Andrew P Fontenot; Scott J Canavera; Laia Gharavi; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  Co-modulation of T cells and B cells enhances the inhibition of inflammation in experimental hypersensitivity pneumonitis.

Authors:  Olivier Courtemanche; Carole-Ann Huppé; Pascale Blais Lecours; Ophélie Lerdu; Joanny Roy; Jean-François Lauzon-Joset; Marie-Renée Blanchet; Mathieu C Morissette; David Marsolais
Journal:  Respir Res       Date:  2022-10-08

5.  Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses.

Authors:  Stephen B Gordon; Rose Malamba; Neema Mthunthama; Elizabeth R Jarman; Kondwani Jambo; Khuzwayo Jere; Eduard E Zijlstra; Malcolm E Molyneux; John Dennis; Neil French
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

6.  Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies.

Authors:  Heng Liu; Harshad P Patil; Jacqueline de Vries-Idema; Jan Wilschut; Anke Huckriede
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

7.  Increased IgG but normal IgA anti-pneumococcal protein antibodies in lung of HIV-infected adults.

Authors:  Andrea M Collins; Sherouk El Batrawy; Stephen B Gordon; Daniela M Ferreira
Journal:  Vaccine       Date:  2013-05-10       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.